ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

January 25, 2013

NCI R01 Payline Falls To 12th Percentile In Fifth Year Of No-Growth Budgets.

March 7, 2008

Georgetown Names Cullen Interim Center Director.

November 3, 2000

NCI To Expand Funds for Cancer Centers, SPOREs, Director Tells House Appropriators

March 29, 2002

Clinton Budget Proposes Increase For AIDS, tuberculosis, In FY94

April 23, 1993

ACS Prostate Cancer Recommendations Move Forward

August 7, 1992